Discover trends, market shifts, and competitive outlooks for the soliris global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Has The Soliris Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The market size of Soliris has witnessed robust growth in the past few years. Projected growth indicates an increase from $1,880.37 million in 2024 to $2,030.44 million in 2025, maintaining a compound annual growth rate (CAGR) of 8.0%. This substantial growth during the historic period is a result of regulatory approvals, a rise in awareness for rare diseases, escalating demands for complement inhibition, extension of indications, and a surge in diagnostic rates.
In the coming years, the Soliris market is projected to witness significant expansion. With a compound annual growth rate (CAGR) of 7.7%, it is anticipated to reach $3,734.88 million by the year 2029. Factors such as the rising occurrence of diseases mediated by complement, advancements in the field of gene therapy, increasing access to the market in emerging regions, the emergence of biosimilars, and improved patient adherence are likely to contribute to the growth during the forecast period. The forecast period will also see key trends like the embracing of amalgamation therapies, surge in patient-oriented treatments, a move towards individualized medicine, the increasing implementation of digital health technology, and a focus on cost-effective and value-oriented care.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp
What External and Internal Drivers Are Contributing to the Growth of the Soliris Market?
The soliris market is predicted to expand due to the rising prevalence of uncommon blood ailments such as varied blood production, component anomalies, and coagulation disorders include hemophilia, sickle cell anemia, and thalassemia. The increment in these illnesses is mainly due to advanced diagnostic procedures, broader awareness, as well as hereditary and environmental triggers. Soliris, which blocks the C5 complement protein, assists patients with such disorders by halting excessive complement activation, helping to prevent serious complications such as hemolysis and organ damage, and ultimately improving patient management and disease outcomes. For example, NHS England reported in May 2024 that about 17,000 people in England have sickle cell disease with 250 new diagnoses each year. This rise in rare blood disorders is boosting the soliris market. The soliris market is on course for further expansion, propelled by a surge in investment in research into rare diseases. The increase in funds for such research is fueled by the realization of unmet medical requirements, advancements in genomics and promising new therapies that could enhance patient outcomes. The allocation of funds towards the study of rare diseases can help soliris by improving understanding of neglected conditions, thereby raising demand for efficient therapies. For example, in July 2023, the UK’s Department of Health and Science Care contributed substantial funding, which included USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource, to link genetic data to clinical characteristics across 50 rare diseases in order to improve diagnostics and treatment procedures. Consequently, the boost in funding for rare disease research is driving the growth of the soliris market.
What Segment Types Define the Soliris Market Structure?
The solirismarket covered in this report is segmented –
1) By Type: Plasma Exchange; Plasma Infusion
2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH); Atypical Hemolytic Uremic Syndrome (AHUS)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=19933&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Soliris Market?
North America was the largest region in the Soliris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Soliris Market?
The soliris market’s primary trend involves concentrating on developing biologic medicines catered towards neuromyelitis optica spectrum disorder (NMOSD) to magnify treatment choices for uncommon blood disorders. This stands as a noteworthy progress in the treatment of NMOSD, a rare and debilitating condition characterized by autoimmune responses affecting the central nervous system. The progress provides a feasible therapy option to reduce episodes and restrain additional neurological damage. To illustrate, AstraZeneca PLC, a pharmaceutical firm based in the UK, was granted approval for Soliris (eculizumab) from China’s National Medical Products Administration (NMPA) in October 2023. The medicine tackles adult patients with NMOSD who tested positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This is noteworthy as the first and sole complement inhibitor ratified for NMOSD treatment in China.
View the full report here:
https://www.thebusinessresearchcompany.com/report/soliris-global-market-report
What Is the Definition of the Soliris Market?
Soliris (eculizumab) is a monoclonal antibody developed by Alexion Pharmaceuticals. It inhibits the complement protein C5, reducing inflammation and damage caused by an overactive immune system. Soliris is primarily used to treat rare diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG).
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19933
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
